These three growth stocks are down big. The decline in stock price could mean a great buying opportunity for long-term investors.
News & Analysis: GoodRx Holdings, Inc.
The best buy on this list trades over a ridiculous 60 times its future earnings.
Some of the drug discounter's growth is out of the company's hands.
This healthcare tech company has helped consumers save a cumulative $25 billion on prescription drugs. But that doesn't necessarily make its stock a buy.
Revenue was ahead of expectations, but investors can't shake this massive net loss.
Prescription transaction volume fueled strong revenue growth for the healthcare company in Q4.
GDRX earnings call for the period ending December 31, 2020.
How have these big healthcare IPOs been doing?
It appears to have benefited from traders bidding up stocks with a lot of short interest.
Ten years from now, our healthcare system probably won't look like what it does today.